know that some repost these, but will not risk losing my subscription. will requote some comments @ harvard club meeting, West is determined to "unlock Biotimes shareholder value" in 15', and "you should expect continued unlocking of these assets".
We will see the comercialization of the diagnostic for colon, breast, and bladder cancer and the possible completion of the Renevia trial.
Hy Stem is now FDA approved and currently marketed.
Cancer research inst. UK investing $30 million.
Cal inst. of regenerative meds contributing $
Not to mention the multitude other trials in different phases.
This company is a monster.
Yes, you can wait until 16', but you will be paying a double digit and possibly triple digit price.
Good luck lads - GO BTX
News 
Market Data 
Discover 
